EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.eqrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2022 | Neutral → Underweight | JP Morgan | |
| 11/11/2022 | $8.00 → $5.00 | Buy → Neutral | Goldman |
| 11/11/2022 | $5.60 → $3.20 | Buy → Hold | Jefferies |
| 8/16/2022 | $5.50 | Neutral | JP Morgan |
| 6/13/2022 | $8.00 | Buy | Goldman |
| 4/22/2022 | Outperform | Cowen | |
| 3/18/2022 | $5.60 | Buy | Jefferies |
15-12G - EQRx, Inc. (0001843762) (Filer)
EFFECT - EQRx, Inc. (0001843762) (Filer)
EFFECT - EQRx, Inc. (0001843762) (Filer)
EFFECT - EQRx, Inc. (0001843762) (Filer)
POS AM - EQRx, Inc. (0001843762) (Filer)
POS AM - EQRx, Inc. (0001843762) (Filer)
S-8 POS - EQRx, Inc. (0001843762) (Filer)
POS AM - EQRx, Inc. (0001843762) (Filer)
S-8 POS - EQRx, Inc. (0001843762) (Filer)
25-NSE - EQRx, Inc. (0001843762) (Subject)
NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo
Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link
For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapyEnded 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 20282023 cash used in operations is expected to be less than $275 million, enabled by efforts to increase operational efficiencies including a reduction in workforce CAMBRIDGE, Mass., Feb.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST. A live and archived webcast of the presentation will be available by visiting the News & Events section of EQRx's website, and selecting Events & Presentations, at investors.eqrx.com. About EQRxEQRx is a new type of pharmaceutical company committed
Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRx's second from the United Kingdom's Medicines and Healthcare products Regulatory Agency after acceptance of aumolertinib MAA earlier this year CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today anno
Submission is EQRx's first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the European Medicines Agency (EMA) has accepted for review its marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor
Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.'s MHRASugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab plus chemotherapy in Stage IV NSCLC in the U.S.; continue to pursue ex-U.S. approvals based on existing dataLate-stage pipeline: Prioritize development of aumolertinib and lerociclib, which could form the basis of future combination therapies for multiple cancer typesU.S. commercial strategy: Adopt market-based pricing for aumolertinib and lerociclib in the U.S. only Strong financial position: $1.5 billion cash and shor
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST. A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx's website, and selecting Events & Presentations, at investors.eqrx.com. About EQRxEQRx is a new type of pharmaceutical company committed to developing and delivering innovative med
SC 13G/A - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
SC 13G - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
SC 13G - EQRx, Inc. (0001843762) (Subject)
SC 13G/A - EQRx, Inc. (0001843762) (Subject)
SC 13G - EQRx, Inc. (0001843762) (Subject)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
JP Morgan downgraded EQRx from Neutral to Underweight
Goldman downgraded EQRx from Buy to Neutral and set a new price target of $5.00 from $8.00 previously
Jefferies downgraded EQRx from Buy to Hold and set a new price target of $3.20 from $5.60 previously
JP Morgan initiated coverage of EQRx with a rating of Neutral and set a new price target of $5.50
Goldman initiated coverage of EQRx with a rating of Buy and set a new price target of $8.00
Cowen initiated coverage of EQRx with a rating of Outperform
Jefferies initiated coverage of EQRx with a rating of Buy and set a new price target of $5.60
Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link
For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapyEnded 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 20282023 cash used in operations is expected to be less than $275 million, enabled by efforts to increase operational efficiencies including a reduction in workforce CAMBRIDGE, Mass., Feb.
Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRx's second from the United Kingdom's Medicines and Healthcare products Regulatory Agency after acceptance of aumolertinib MAA earlier this year CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today anno
Submission is EQRx's first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the European Medicines Agency (EMA) has accepted for review its marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor
Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.'s MHRASugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab plus chemotherapy in Stage IV NSCLC in the U.S.; continue to pursue ex-U.S. approvals based on existing dataLate-stage pipeline: Prioritize development of aumolertinib and lerociclib, which could form the basis of future combination therapies for multiple cancer typesU.S. commercial strategy: Adopt market-based pricing for aumolertinib and lerociclib in the U.S. only Strong financial position: $1.5 billion cash and shor
CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November 10, 2022 at 8:00 a.m. ET to report its third quarter 2022 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link (registration link) to receive dial-in details. Participant
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx's first regulatory submission (aumolertinib) for review; first sugemalimab regulatory submission expected ex-U.S. in 2H 2022; continue to engage in constructive conversations with the U.S. FDAPresented compelling new clinical data at recent medical meetings, including results from a study of aumolertinib in patients with NSCLC and CNS metastases (ASCO) and a late-breaking oral presentation of final PFS results of sugemalimab in Stage III NSCLC (WCLC)Expanded Global Buyers Club to over 210 million lives covered by payers and healt
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free survival versus placebo in patients with unresectable Stage III non-small cell lung cancer (NSCLC)There are currently no immunotherapy consolidation treatments in the U.S. or Europe approved for patients with unresectable Stage III NSCLC who have received sequential chemoradiotherapy CAMBRIDGE, Mass., Aug. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radicall